The Walgreens Prescription Savings Club Settlement is a $100 million class action settlement approved on March 31, 2026, but it resolves allegations about prescription pricing deception—not a privacy breach. Walgreens allegedly reported inflated “usual and customary” (UC) prices to insurance companies while offering lower prices to members of its Prescription Savings Club, causing customers to overpay copays and insurers to overpay claims. This settlement covers prescriptions filled at Walgreens locations between January 1, 2007, and November 18, 2024. Despite the word “privacy” sometimes appearing in headlines about this case, the core issue is pricing manipulation, and the settlement focuses on reimbursement for overcharged customers and insurers—not data breach exposure or medical information misuse.
Table of Contents
- What Are the Allegations in the Walgreens Prescription Pricing Case?
- Who Is Eligible for This Settlement and What Is the Claims Status?
- How Much Money Is Available and How Will Payments Be Distributed?
- What Is the Current Settlement Status as of July 2026?
- What Are the Key Limitations and Important Caveats?
- How Does the Claims Administration Process Work?
- Understanding Walgreens’ Historical Privacy Issues and How They Differ From This Settlement
What Are the Allegations in the Walgreens Prescription Pricing Case?
The lawsuit, Russo et al. v. Walgreen Co., centers on how walgreens handled prescription pricing for insured customers. The plaintiff alleged that Walgreens systematically reported artificially high “usual and customary” prices to insurance companies as the standard retail price, then offered lower prices through its Prescription Savings Club.
This two-tier pricing structure meant that insured customers with copay structures based on the inflated UC price ended up paying more out-of-pocket than customers using the Prescription Savings Club. For example, if Walgreens reported a UC price of $50 for a medication but offered it to Prescription Savings Club members for $30, an insured patient with a percentage-based copay would be charged based on the $50 figure rather than the actual discounted rate available in-store. Insurance companies also suffered financial harm through this scheme because they based their reimbursements to Walgreens on the inflated UC prices. When Walgreens submitted claims for the higher UC amount but actually filled the prescription at the lower Prescription Savings Club price, the insurer overpaid—and those inflated reimbursement costs were passed along to employers and individual policyholders through higher premiums. The lawsuit argued that this practice violated consumer protection laws by failing to disclose that the UC prices reported to insurers did not reflect actual in-store pricing available to Walgreens customers.
Who Is Eligible for This Settlement and What Is the Claims Status?
The settlement class includes anyone who filled prescriptions at a Walgreens pharmacy between January 1, 2007, and November 18, 2024, while covered by health insurance. This is a direct claims settlement, meaning class members must file a claim to receive compensation—there is no automatic payment for all eligible customers. However, the original claim deadline of April 17, 2025, has already passed, and the settlement administrator (A.B. Data) is no longer accepting new claims from individual customers as of July 2026.
If you did not submit a claim before the April 17, 2025, deadline, you are barred from receiving individual compensation under this settlement. The settlement also includes a significant payment to third-party payers (insurance companies, pharmacy benefit managers, and employers) that funded the prescriptions—these entities are receiving claims processing and reimbursement through separate channels. Individual claimants are only eligible to recover a prorated share of 20% of the settlement fund, while 80% is reserved for third-party payers. This weighting means that individual claimant recoveries are typically modest unless someone filled a very large number of prescriptions at Walgreens during the class period. For instance, someone who filled two or three prescriptions during the 17-year class period would receive far less than someone who relied on Walgreens for all prescriptions for chronic conditions requiring monthly refills.
How Much Money Is Available and How Will Payments Be Distributed?
The total settlement amount is $100 million, but substantial deductions come before individual claimants see any money. The settlement agreement permits attorney fees of up to 30% of the settlement fund ($30 million), which goes to the plaintiffs’ legal team. Administrative costs for the claims process (including settlement administration, settlement notice, claims review, and payment processing) are capped at $3 million. Additional costs for class representative service awards (payments to the named plaintiffs who brought the case) further reduce the pool available to individual claimants.
After these deductions, the remaining settlement fund is divided with 80% going to third-party payers and 20% available for individual claimant reimbursement. Payments to individual claimants are calculated on a prorated basis according to the total amount of eligible prescriptions each person filled during the class period. Someone who submitted a claim covering $500 worth of prescriptions would receive a larger share of the individual claimant pool than someone whose claims totaled $100. As of July 2026, no final payments have been issued yet, as the settlement administrator is still processing all submitted claims and verifying their validity.
What Is the Current Settlement Status as of July 2026?
The settlement received final court approval from U.S. District Judge Edmond E. Chang of the Northern District of Illinois on March 31, 2026. The 30-day post-judgment period for appeals has passed without a successful challenge to the settlement. As of July 2026, the settlement administrator A.B.
data is actively processing claims and contacting class members who submitted deficient claims (claims missing required documentation or information). Class members who submitted incomplete claims are being given an opportunity to cure deficiencies and provide additional proof of their prescription purchases and eligibility. The expected payment timeline is mid-to-late 2026, assuming no major claims processing delays and no successful post-judgment appeals by either the defendant or class members. The official settlement website, SavingsClubSettlement.com, provides up-to-date information on claim processing status, claim payment schedules, and administrator contact information. You can check the status of your claim through that portal if you submitted one before the April 17, 2025, deadline. The settlement is considered “final” in judicial terms as of July 2026, but payments to individual claimants are still pending final reconciliation and calculation of the individual claim pool.
What Are the Key Limitations and Important Caveats?
The most critical limitation is that the claims deadline of April 17, 2025, has passed, and the settlement is no longer accepting new claims from individuals. If you are aware of the settlement after this date, you cannot file a claim to recover compensation. This cutoff is firm—there are no exceptions or extensions for late claims once the deadline passes. Anyone who missed the deadline is permanently barred from receiving compensation through this settlement, even if they were eligible and were not aware the deadline existed.
This creates a significant financial penalty for people who did not monitor class action settlement news or read the settlement notice if they were mailed one. Another important caveat is that this settlement does not address any potential privacy breaches or data security issues. Walgreens’ past privacy violations—including a 2013 HIPAA settlement for $1.44 million relating to a pharmacist improperly accessing patient medical records—are separate legal matters. This settlement is narrowly focused on prescription pricing and does not award compensation for any exposure of personal health information or privacy violations related to how Walgreens handled customer data. If you are seeking compensation for a privacy breach, you would need to investigate a different legal claim or past settlement.
How Does the Claims Administration Process Work?
The settlement administrator A.B. Data manages the claims process and serves as the central point of contact for all settlement matters. When a claim is submitted, the administrator reviews it for completeness and eligibility based on the information provided (prescription records, insurance carrier information, dates of service, and amounts paid). If documentation is missing or insufficient, A.B.
Data contacts the claimant with a notice of deficiency and allows a specific period to submit additional proof—such as pharmacy receipts, insurance explanation of benefits (EOB) forms, or historical prescription records obtained from Walgreens or the insurance carrier. Once a claim is approved, the administrator calculates the individual’s pro rata share of the 20% individual claimant portion of the settlement fund based on their total eligible prescription spending during the class period. Payments are issued via check or electronic transfer, depending on the claimant’s preference selected during the claims process. The administrator publishes periodic updates on settlement progress, including the number of claims received, approved, and pending. As of July 2026, hundreds of thousands of claims are in various stages of review, and the administrator is working through the backlog before the final payment distribution date.
Understanding Walgreens’ Historical Privacy Issues and How They Differ From This Settlement
While this settlement involves Walgreens and customer records, it is important to distinguish it from actual privacy breaches and HIPAA violations. In 2013, Walgreens settled a case for $1.44 million with the State of Indiana after a Walgreens pharmacist improperly accessed patient prescription records without authorization and used that access to harass customers. That case involved unauthorized access to sensitive health information—a true privacy violation. In contrast, the Prescription Savings club Settlement involves pricing practices where customer information was used according to normal business operations, but the pricing methodology itself was allegedly misleading and inflated.
Additionally, the Department of Justice required Walgreens to pay $350 million as part of a 2024 federal settlement for illegally filling opioid prescriptions and failing to report suspicious orders to the Drug Enforcement Administration. This settlement also involved prescription records, but the violation was about prescription fulfillment practices and regulatory compliance, not customer privacy. The Prescription Savings Club Settlement is distinct from all of these cases because it addresses a business practice related to price reporting, not unauthorized data access, data breaches, or improper regulatory compliance. Anyone seeking information about Walgreens privacy violations or opioid settlement eligibility should research those cases separately, as they have their own deadlines and eligibility requirements.
- —